Cargando…

Correction: Blood Amyloid Beta Levels in Healthy, Mild Cognitive Impairment and Alzheimer’s Disease Individuals: Replication of Diastolic Blood Pressure Correlations and Analysis of Critical Covariates

Detalles Bibliográficos
Autores principales:	Ruiz, Agustín, Pesini, Pedro, Espinosa, Ana, Pérez-Grijalba, Virginia, Valero, Sergi, Sotolongo-Grau, Oscar, Alegret, Montserrat, Monleón, Inmaculada, Lafuente, Asunción, Buendía, Mar, Ibarria, Marta, Ruiz, Susana, Hernández, Isabel, San José, Itziar, Tárraga, Lluís, Boada, Mercè, Sarasa, Manuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878926/ http://dx.doi.org/10.1371/annotation/0f80896d-487c-4323-8eeb-774b6d517005

Ejemplares similares

Blood Amyloid Beta Levels in Healthy, Mild Cognitive Impairment and Alzheimer’s Disease Individuals: Replication of Diastolic Blood Pressure Correlations and Analysis of Critical Covariates
por: Ruiz, Agustín, et al.
Publicado: (2013)

Association between cell-bound blood amyloid-β(1–40) levels and hippocampus volume
por: Sotolongo-Grau, Oscar, et al.
Publicado: (2014)

Reliable Measurements of the β-Amyloid Pool in Blood Could Help in the Early Diagnosis of AD
por: Pesini, Pedro, et al.
Publicado: (2012)

Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study
por: Pérez-Grijalba, Virginia, et al.
Publicado: (2019)

Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype
por: Espinosa, Ana, et al.
Publicado: (2017)

Safety, tolerability and immunogenicity of an active anti-Aβ(40) vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial
por: Lacosta, Ana-María, et al.
Publicado: (2018)

Patient Engagement: The Fundació ACE Framework for Improving Recruitment and Retention in Alzheimer’s Disease Research
por: Boada, Mercè, et al.
Publicado: (2018)

Cut-off Scores of a Brief Neuropsychological Battery (NBACE) for Spanish Individual Adults Older than 44 Years Old
por: Alegret, Montserrat, et al.
Publicado: (2013)

Correction: Cut-off Scores of a Brief Neuropsychological Battery (NBACE) for Spanish Individual Adults Older than 44 Years Old
por: Alegret, Montserrat, et al.
Publicado: (2014)

The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening
por: Rosende-Roca, Maitee, et al.
Publicado: (2021)

BIOFACE: A Prospective Study of Risk Factors, Cognition, and Biomarkers in a Cohort of Individuals with Early-Onset Mild Cognitive Impairment. Study Rationale and Research Protocols
por: Esteban de Antonio, Ester, et al.
Publicado: (2021)

The MAPT H1 Haplotype Is a Risk Factor for Alzheimer’s Disease in APOE ε4 Non-carriers
por: Sánchez-Juan, Pascual, et al.
Publicado: (2019)

Managing Clinical Trials for Alzheimer’s Disease During the COVID-19 Crisis: Experience at Fundació ACE in Barcelona, Spain
por: Abdelnour, Carla, et al.
Publicado: (2020)

Social Representation of Dementia: An Analysis of 5,792 Consecutive Cases Evaluated in a Memory Clinic
por: Cañabate, Pilar, et al.
Publicado: (2017)

Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer’s Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial
por: Boada, Mercè, et al.
Publicado: (2017)

A randomized, open-label clinical trial in mild cognitive impairment with EGb 761 examining blood markers of inflammation and oxidative stress
por: Morató, Xavier, et al.
Publicado: (2023)

Automatized FACEmemory® scoring is related to Alzheimer’s disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort
por: Alegret, Montserrat, et al.
Publicado: (2022)

The Spanish version of Face-Name Associative Memory Exam (S-FNAME) performance is related to amyloid burden in Subjective Cognitive Decline
por: Sanabria, Angela, et al.
Publicado: (2018)

Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI)
por: de Rojas, Itziar, et al.
Publicado: (2018)

Genome-wide significant risk factors on chromosome 19 and the APOE locus
por: Moreno-Grau, Sonia, et al.
Publicado: (2018)

Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer’s disease in individuals with subjective cognitive decline
por: Pascual-Lucas, María, et al.
Publicado: (2023)

Plasma extracellular vesicles reveal early molecular differences in amyloid positive patients with early-onset mild cognitive impairment
por: Cano, Amanda, et al.
Publicado: (2023)

Personality Factors and Subjective Cognitive Decline: The FACEHBI Cohort
por: Muñoz, Nathalia, et al.
Publicado: (2020)

Outstanding Phenotypic Differences in the Profile of Amyloid-β between Tg2576 and APPswe/PS1dE9 Transgenic Mouse Models of Alzheimer’s Disease
por: Allué, José Antonio, et al.
Publicado: (2016)

Interaction of neuropsychiatric symptoms with APOE ε4 and conversion to dementia in MCI patients in a Memory Clinic
por: Sergi, Valero, et al.
Publicado: (2020)

Author Correction: Interaction of neuropsychiatric symptoms with APOE ε4 and conversion to dementia in MCI patients in a Memory Clinic
por: Valero, Sergi, et al.
Publicado: (2021)

Exploring Genetic Associations of Alzheimer’s Disease Loci With Mild Cognitive Impairment Neurocognitive Endophenotypes
por: Espinosa, Ana, et al.
Publicado: (2018)

Harnessing acoustic speech parameters to decipher amyloid status in individuals with mild cognitive impairment
por: García-Gutiérrez, Fernando, et al.
Publicado: (2023)

Neuropsychiatric profiles and conversion to dementia in mild cognitive impairment, a latent class analysis
por: Roberto, Natalia, et al.
Publicado: (2021)

Establishing In-House Cutoffs of CSF Alzheimer’s Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort
por: Orellana, Adelina, et al.
Publicado: (2022)

Identification of undiagnosed dementia cases using a web‐based pre‐screening tool: The MOPEAD project
por: Rodrigo, Adrián, et al.
Publicado: (2021)

Evaluation of macular thickness and volume tested by optical coherence tomography as biomarkers for Alzheimer’s disease in a memory clinic
por: Sánchez, Domingo, et al.
Publicado: (2020)

Neuropsychiatric Profile as a Predictor of Cognitive Decline in Mild Cognitive Impairment
por: Roberto, Natalia, et al.
Publicado: (2021)

Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Aβ(40) and Aβ(42) Peptides in Plasma
por: Pérez-Grijalba, Virginia, et al.
Publicado: (2016)

Total Aβ(42)/Aβ(40) ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis
por: Doecke, James D., et al.
Publicado: (2020)

From Face-to-Face to Home-to-Home: Validity of a Teleneuropsychological Battery
por: Alegret, Montserrat, et al.
Publicado: (2021)

Natural Non-Trasgenic Animal Models for Research in Alzheimer’s Disease
por: Sarasa, Manuel, et al.
Publicado: (2009)

Usefulness of peripapillary nerve fiber layer thickness assessed by optical coherence tomography as a biomarker for Alzheimer’s disease
por: Sánchez, Domingo, et al.
Publicado: (2018)

Author Correction: Usefulness of peripapillary nerve fiber layer thickness assessed by optical coherence tomography as a biomarker for Alzheimer’s disease
por: Sánchez, Domingo, et al.
Publicado: (2019)

Blood Markers in Healthy-Aged Nonagenarians: A Combination of High Telomere Length and Low Amyloidβ Are Strongly Associated With Healthy Aging in the Oldest Old
por: Fernández-Eulate, Gorka, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lnblvfli9ds95sc74sq7007dem